Ron Zwanziger has just started his third company, having just sold the last one for $1.3 billion to Johnson & Johnson. As part of the deal with J&J, certain assets were transferred to the new company, Inverness Medical Innovations, which, at the time of its creation, had $24 million in half-year sales, $40 million on its balance sheet, and worldwide operations. How were Zwanziger and his team going to transform these disparate assets into a company worth $7 billion in the coming seven years?